Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 Nov 11, 2024
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 Nov 7, 2024
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia Aug 26, 2024
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq Aug 23, 2024
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update Aug 13, 2024
Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 Aug 8, 2024
Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months Jul 23, 2024
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million Jul 22, 2024
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape Jun 27, 2024